A Look At Ypsomed Holding’s (SWX:YPSN) Valuation After Strong Full Year 2026 Earnings Results

Why Ypsomed Holding’s latest earnings matter for shareholders Ypsomed Holding (SWX:YPSN) just released full year results to March 31, 2026, reporting net income of CHF 221.93 million and basic earnings per share of CHF 16.31 from continuing operations. These figures compare with net income of CHF 87.5 million and basic earnings per share of CHF 6.41 a year earlier, putting earnings firmly in focus for anyone tracking the stock’s recent move. See our latest analysis for Ypsomed Holding. The latest results arrive after a sharp run in the stock, with a 1 month share price return of 20.82% and 3 month share price return of 25.23%, even though the 1 year total shareholder return is down 11.45% while the 5 year total shareholder return is up 128.50%. This suggests short term momentum has picked up against a still strong longer term record. If these earnings have you rethinking your healthcare exposure, it can be useful to scan other potential opportunities in the sector using our screener for 126 healthcare AI stocks. With earnings per share at CHF 16.31, a value score of 5, an indicated intrinsic discount of 41.80% and a share price still below the average analyst target, should you view Ypsomed as undervalued, or is the market already pricing in future growth? Most Popular Narrative: 12.3% Undervalued Ypsomed Holding's most followed narrative puts fair value at CHF 387.82 versus a last close of CHF 340, framing the latest earnings in a valuation gap. Ypsomed's shift to a B2B model and local manufacturing may streamline operations, improve focus, and reduce geopolitical risks, which could enhance margins and earnings. The company's expanded manufacturing capacity, including investment in new assembly lines and doubling its tool shop, positions Ypsomed to meet future demand, especially in fast-growing segments like auto-injectors, potentially boosting revenues. Read the complete narrative. Want to see what is baked into that fair value of CHF 387.82? Revenue pacing, margin gains and the profit multiple all pull in different directions. Result: Fair Value of CHF 387.82 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on Ypsomed executing its expansion and divestment plans cleanly, since any hiccups in large capacity projects or GLP 1 partnerships could quickly challenge that narrative. Find out about the key risks to this Ypsomed Holding narrative. Next Steps With both risks and rewards on the table, do these results leave you convinced or cautious, and how quickly do you want to firm up your view? To weigh the upside against the concerns in more detail, take a closer look at the 4 key rewards and 1 important warning sign. Looking for more investment ideas? If you stop your research here, you could miss stocks that better fit your goals. Keep building your shortlist and let the numbers do the filtering. Spot potential bargains early by scanning screener containing 531 high quality undiscovered gems that combine solid fundamentals with lower market attention. Strengthen your core holdings by reviewing companies in the solid balance sheet and fundamentals stocks screener (390 results) that focus on resilience and financial discipline. Target income-focused opportunities by checking out 480 dividend fortresses that aim for higher yields with an emphasis on durability. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.